Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

Alkermes

Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of Stockholders scheduled for November 4, 2022. Proposal Two, authorization of a Reverse Stock Split, remains on the ballot. This proposal would give Acorda's Board of Directors the ability to implement a reverse stock split of Acorda's stock. Propos

Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Resignation of Chief Operating Officer

Acorda Therapeutics Announces Resignation of Chief Operating Officer

Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - CEO Mike Gesser - CFO Operator Ladies and gentlemen, welcome to Acorda Therapeutics' Second Quarter 2022 Financial and Business Update. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcript

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2022 Financial Results

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

Kinross Gold

Rigel Pharmaceuticals

Here are three penny stocks to add to your watchlist right now The post Best Penny Stocks to Watch as the Market Crashes Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch as the Market Crashes Again

Acorda Therapeutics Inc (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.  INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in.

Why Acorda Therapeutics Shares Gaining Today?

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. (1) Under the terms of the distribution and supply agreements, Acorda will receive a

Esteve Launches INBRIJA® in Germany

Bit Origin Ltd

Globalstar

Here's what you need to know about trading penny stocks on June 6th, 2022 The post What to Know About Buying Penny Stocks on June 6th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 6th

Start Time: 16:30 January 1, 0000 5:02 PM ET Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 PM ET Company Participants Ron Cohen - Founder, President and CEO Mike Gesser - CFO Tierney Saccavino - EVP, Corporate Communications Conference Call Participants Muzamil Saleem - H.C. Wainwright Operator Good afternoon.

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2022 Results - Earnings Call Transcript

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2022 Financial Results

Acorda Therapeutics Reports First Quarter 2022 Financial Results

ARDSLEY, N.Y. & PANAMA CITY--(BUSINESS WIRE)--Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022

Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--John Varian joins Acorda Therapeutics Board of Directors

John Varian Joins Acorda Therapeutics Board of Directors

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2021 Results - Earnings Call Transcript

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

Acorda Therapeutics (NASDAQ:ACOR) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement.

News for Acorda Therapeutics Stock (ACOR)